Bratisl Lek Listy. 2021;122(8):538-547. doi: 10.4149/BLL_2021_086.
OBJECTIVES: The most promising strategy for managing COVID-19 pandemic is achieving sufficient vaccination rate worldwide. The question is how many people will be willing to get vaccinated. STUDY DESIGN: We systematically reviewed peer-reviewed manuscripts monitoring people´s intention to receive a vaccine against COVID-19. METHODS: Up to December 28, 2020 we identified 62 relevant peer-reviewed articles in PubMed, Web of Science, Scopus and GoogleScholar. RESULTS: Total sample size was 118 855 respondents with overall average COVID-19 vaccine acceptance rate of 72.5% which is "just" the level estimated to be sufficient for reaching herd immunity threshold. Surprisingly, healthcare workers showed smaller interest in receiving the vaccine when compared to general adult population and university students. On the other hand, their attitude to vaccination did not change over time. In case of general adult population, the longer the pandemic lasts, the smaller proportion of population wants to get vaccinated. Vaccination intentions were independent of gross domestic product and human development index. CONCLUSION: Willingness of population to receive COVID-19 is just at the herd immunity threshold and it is decreasing over time (Tab. 2, Fig. 3, Ref. 110). Keywords: vaccination, survey, COVID-19, pandemic, review.
目的:管理 COVID-19 大流行最有希望的策略是在全球范围内实现足够高的疫苗接种率。问题是有多少人愿意接种疫苗。
研究设计:我们系统地回顾了监测人们对 COVID-19 疫苗接种意愿的同行评议文献。
方法:截至 2020 年 12 月 28 日,我们在 PubMed、Web of Science、Scopus 和 Google Scholar 中确定了 62 篇相关的同行评议文章。
结果:总样本量为 118855 名受访者,总体平均 COVID-19 疫苗接受率为 72.5%,这只是达到群体免疫阈值估计所需的水平。令人惊讶的是,与一般成年人口和大学生相比,医护人员对接种疫苗的兴趣较小。另一方面,他们对疫苗接种的态度并没有随着时间的推移而改变。对于一般成年人群体,大流行持续的时间越长,愿意接种疫苗的人群比例就越小。疫苗接种意愿与国内生产总值和人类发展指数无关。
结论:人群接种 COVID-19 的意愿仅达到群体免疫阈值,且随着时间的推移呈下降趋势(表 2、图 3、参考文献 110)。关键词:疫苗接种、调查、COVID-19、大流行、综述。
JAMA Netw Open. 2020-10-1
Int J Environ Res Public Health. 2021-3-8
Glob Health Res Policy. 2021-1-29
Florence Nightingale J Nurs. 2024-2-28
J Infect Public Health. 2023-1
Microbiol Res. 2022-12
Vaccines (Basel). 2022-9-3